XIEJINGYUAN
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy (NCT05824390) | XIEJINGYUAN | 2020-06-20 |
Track XIEJINGYUAN automatically
Every clearance here is in the API, with alerts when new ones post.